Dominic KingSmith - Crescita Therapeutics VP Devel
| CRRTF Stock | USD 0.45 0.00 0.00% |
Insider
Dominic KingSmith is VP Devel of Crescita Therapeutics
| Phone | 905 673 4297 |
| Web | https://www.crescitatherapeutics.com |
Crescita Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0227 % which means that it generated a profit of $0.0227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0318 %, meaning that it generated $0.0318 on every $100 dollars invested by stockholders. Crescita Therapeutics' management efficiency ratios could be used to measure how well Crescita Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | INSIDER Age | ||
| Scott Landers | Grey Cloak Tech | N/A | |
| Kevin Pitts | Grey Cloak Tech | 63 | |
| Robert Madden | Grey Cloak Tech | 51 | |
Management Performance
| Return On Equity | 0.0318 | |||
| Return On Asset | 0.0227 |
Crescita Therapeutics Leadership Team
Elected by the shareholders, the Crescita Therapeutics' board of directors comprises two types of representatives: Crescita Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crescita. The board's role is to monitor Crescita Therapeutics' management team and ensure that shareholders' interests are well served. Crescita Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crescita Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominic KingSmith, VP Devel | ||
| Francois Lafortune, Ex GM |
Crescita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Crescita Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0318 | |||
| Return On Asset | 0.0227 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 3.64 M | |||
| Shares Outstanding | 20.4 M | |||
| Shares Owned By Insiders | 7.30 % | |||
| Price To Earning | 490.00 X | |||
| Price To Book | 0.66 X | |||
| Price To Sales | 0.41 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Crescita Pink Sheet
Crescita Therapeutics financial ratios help investors to determine whether Crescita Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.